There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (1)

Official Titles

Official Titles - Senate

Official Titles as Introduced

A concurrent resolution urging Japan to honor its commitments under the 1986 Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals, and for other purposes.

Actions Overview (1)

11/10/2003Introduced in Senate

All Actions (1)

11/10/2003Read twice and referred to the Committee on Foreign Relations. (text of measure as introduced: CR S14364)
Action By: Senate

Cosponsors (3)

* = Original cosponsor
CosponsorDate Cosponsored
Sen. Bayh, Evan [D-IN]* 11/10/2003
Sen. Gregg, Judd [R-NH] 01/22/2004
Sen. Santorum, Rick [R-PA] 02/09/2004

Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
Senate Foreign Relations11/10/2003 Referred to

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.

Latest Summary (1)

There is one summary for S.Con.Res.80. View summaries

Shown Here:
Introduced in Senate (11/10/2003)

Urges Japan to honor its commitments under the Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals by: (1) reducing regulatory barriers to the approval and adoption of new medical technologies; (2) establishing reasonable agency performance goals for premarket approvals and an appropriate, risk-based postmarket system consistent with globally accepted practices; (3) actively promoting pricing policies that encourage innovation; (4) implementing fair and open processes and rules that do not disproportionately harm United States medical technology products; and (5) providing opportunities for consultation with trading partners.